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Background: Impurity profiling is now receiving critical attention from regulatory authorities. For trace level
quantification of potential genotoxic impurities (PGIs), conventional analytical techniques like high-performance
liquid chromatography (HPLC) and gas chromatography (GC) are inadequate; consequently, there is a great need to
apply hyphenated analytical techniques to develop sensitive analytical methods for the analysis of pharmaceuticals.
Methods: A selective and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was
developed for the simultaneous determination of (4-sulfamoylphenyl)hydrazine hydrochloride (SHH) and
(4-methyl-acetophenone)para-sulfonamide phenylhydrazine hydrochloride (MAP) PGIs in celecoxib active pharmaceutical
ingredient (API). The LC-MS/MS analysis of SHH and MAP PGIs was done on Symmetry C18 (150 mm × 4.6 mm, 3.5 μm)
analytical column, and the mobile phase used was 5.0 mM ammonium acetate-acetonitrile in the ratio of 30:70 (v/v). The
flow rate used was 0.7 mL/min. Triple quadrupole mass detector coupled to positive electrospray ionization operated
in multiple reaction monitoring (MRM) mode was used for the quantification of SHH and MAP PGIs. The method was
validated as per International Conference on Harmonization (ICH) guidelines and was able to quantitate both SHH and
MAP PGIs at 1.0 ppm with respect to 10 mg/mL of celecoxib.
Results: The proposed method was specific, linear, accurate, precise, and robust. The calibration curves show good
linearity between the concentration range of 0.06 and 7.5 ppm for both SHH and MAP PGIs. The correlation coefficient
obtained was >0.9998 in each case. The method has very low limit of detection (LOD) and limit of quantification (LOQ).
The obtained LOD and LOQ values were 0.02 and 0.06 ppm, respectively, for both SHH and MAP PGIs. For both the
PGIs, excellent recoveries of 95.0% to 104.0% were obtained at a concentration range of 0.06 to 3.0 ppm. The
developed method was also applied to determine the SHH and MAP PGIs in three formulation batches of celecoxib.
Conclusions: The proposed method is simple and accurate and is a good quality control tool for the simultaneous
quantitative determination of SHH and MAP PGIs at very low levels in celecoxib during its manufacturing.
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The presence of potential genotoxic impurities (PGIs)
even in smaller quantities may affect the efficacy and
safety of pharmaceutical products. Impurity profiling
is now receiving critical attention from regulatory
authorities. The different pharmacopoeias such as BP
(British pharmacopoeias), USP (United States pharmaco-
poeias), IP (Indian pharmacopoeias), and so on, are slowly* Correspondence: gmchem01@gmail.com
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reproduction in any medium, provided the origincorporating limits to the allowable levels of impurities
present in the active pharmaceutical ingredients (APIs).
Celecoxib is one of the most popular non-steroidal
anti-inflammatory drug (NSAID) and a selective cyclooxy-
genase-2 (COX-2) inhibitor used to treat osteoarthritis,
rheumatoid arthritis, acute pain, painful menstruation,
and menstrual symptoms (Dembo et al. 2005). Celecoxib
also reduces the number of colon and rectum polyps in
patients with familial adenomatous polyposis (Clemett
and Goa 2000; Silverstein et al. 2000). It is chem-
ically named as 4-[5-(4-methylphenyl)-3-(trifluoromethyl)inger. This is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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ture of celecoxib is shown in Figure 1. (4-Sulfamoylphenyl)
hydrazine hydrochloride (SHH) and (4-methyl-acetophe-
none)para-sulfonamide phenylhydrazine hydrochloride
(MAP) are the two important key intermediates used
in the synthesis of celecoxib, which are identified as
PGIs in finished pharmaceutical substances due to their
electrophilic functional groups (Ashby and Tennant 1988;
Muller et al. 2006). Several analytical methods have been
used to determine celecoxib concentrations in human
plasma with various analytical techniques such as high-
performance liquid chromatography-UV (HPLC-UV), liquid
chromatography-mass spectrometry (LC-MS), and liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
(Jalalizadeh et al. 2004; Zarghi et al. 2006; Emami et al.
2006; Chow et al. 2004; Stormer et al. 2003; Abdel-Hamid
et al. 2001; Werner et al. 2002; Bräutigam et al. 2001), and
few methods have been reported for the determination of
impurities in celecoxib using HPLC and LC-MS/MS
(Satyanarayana et al. 2004; Rao et al. 2006; Jadhav and
Shinqare 2005). Ideally, many conventional analytical
instruments in pharmaceutical industry such as HPLC
with UV detection and GC with flame ionization detector
(FID) detection should be employed as the standards in
the first attempt for PGIs analysis. However, there are
some drawbacks with the abovementioned techniques
because HPLC retention times can vary, and some methods
are needed to characterize the impurities on line when theFigure 1 Chemical structure of celecoxib.impurity standards are not available (Hsieh and Korfmacher
2006; Lee and Kems 1999). Therefore, for accurate de-
termination of PGIs at trace levels, the abovemen-
tioned techniques are inadequate; consequently, there
is a great need to develop better analytical methods for
the analysis of such PGIs in pharmaceutical industries.
As a result, various kinds of hyphenated chromatographic
techniques and methodologies have been explored as
useful approaches.
Based on the threshold of toxicological concern (TTC)
of 1.5 μg/person/day, the impurity concentration in cele-
coxib must not exceed 7.5 ppm considering the worst case
scenario where 200-mg daily dose of celecoxib is applied.
To the best of our knowledge, no analytical method for
the simultaneous determination of SHH and MAP PGIs
in celecoxib has been reported in the literature. Therefore,
in the present study, we have developed a simple LC-MS/
MS method that can quantify two PGIs in celecoxib at
permitted levels. The method was validated as per ICH
guidelines in terms of limit of detection (LOD), limit of
quantification (LOQ), linearity, precision, accuracy,
specificity, robustness, and solution stability. The devel-
oped method was also applied to determine SHH and
MAP PGIs in three formulation batches of celecoxib.
Methods
Chemicals and reagents
All chemicals and solvents were of analytical grade. HPLC
grade acetonitrile and ammonium acetate were purchased
from Merck (Mumbai, India). Formic acid, trifluoroacetic
acid, and methanol were obtained in their highest grade
from SD fine chemicals limited (Mumbai, India). Refer-
ence substances of SHH, MAP, and celecoxib with the
highest purity (>99.0) were obtained from Sigma-Aldrich
(St. Louis, MA, USA). High-purity Milli-Q water was used
with the help of Millipore Milli-Q plus purification system
(Bedford, MA, USA).
Preparation of stock and standard solutions
A stock solution of celecoxib (10 mg/mL) was prepared
by dissolving appropriate amount in the methanol. A
stock solution of mixture of PGIs (SHH and MAP) at
1.0 mg/mL was also prepared in methanol. The diluted
stock solution (0.01 mg/mL) was prepared by diluting
1.0 mL of the 1.0 mg/mL solutions to 100 mL with
methanol. Then, 0.1 μg/mL diluted stock solution was
prepared by diluting 1.0 mL of 0.01 mg/mL diluted
stock solution to 100 mL with methanol. The working
standard solution was prepared by weighing accurately
100 mg of celecoxib into 10-mL volumetric flask and
made the solution up to the graduation mark after adding
10 μL of 0.1 μg/mL diluted stock solution to give 10 ng/mL
and 10 mg/mL of PGIs with respect to celecoxib which
corresponds to 1.0 ppm of PGI contamination relative to
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0.06-, 0.5-, 1.0-, 3.0-, 5.0-, and 7.5-ppm concentrations
relative to the drug substance were prepared in the same
manner using 0.5 μg/mL of diluted stock solution. The
concentration of the standard solutions and samples was
optimized to achieve a desired signal-to-noise ratio (S/N)
and good peak shape. All the standards were sonicated
well and filtered through 0.22-μm membrane filters before
the analysis.
Chromatographic conditions
All chromatographic experiments were carried out on a
HPLC consisting of LC-20AD binary gradient pump,
SPD-10AVP UV detector, SIL-10HTC autosampler, and
a column oven CTO-10ASVP (Shimadzu, Switzerland)
system coupled with MS/MS (Applied Biosystems Sciex
API 4000 model, Rotkreuz, Switzerland). The analytical
column used was Symmetry C18 (150 mm × 4.6 mm,
3.5 μm). The mobile phase flow operated in isocratic
mode using 5.0 mM ammonium acetate-acetonitrile in
the ratio of 30:70 (v/v). The flow rate of the mobile phase
was set at 0.7 mL/min, and the column oven temperature
was maintained at 40°C. The injection volume was 10 μL.
All the solutions were filtered through 0.22-μm nylon
filter before the analysis.
Mass spectrometer
The MS/MS system used was an Applied Biosystems
Sciex API 4000 triple quadrupole mass spectrometer
with electrospray ionization (ESI) probe operated in
positive polarity. Multiple reaction monitoring (MRM)
mode was selected for the quantification of SHH and
MAP PGIs, and the data acquisition and processing
were conducted using the Analyst 1.5.1 software. Typical
operating conditions were as follows: ion spray voltage
5,500 V, source temperature 410°C, declustering potential
(50 and 55 V), entrance potential (10 and 10 V), collision
energy (25 and 20 V), respectively, for both SHH and
MAP PGIs. The curtain gas flow, ion source gas 1, and
ion source gas 2 nebulization pressure were maintained as
25, 30, and 35 psi, respectively. Electrospray ionization
in positive MRM mode was used for the quantification
of SHH and MAP PGIs at their transition ion pairs of
m/z 188.2→99.2 (protonated) and m/z 304.2→209.2
(protonated), respectively. Celecoxib was monitored with
its transition ion pair m/z 382.2→214.1 (protonated).
Method validation
To demonstrate the feasibility of the newly developed
method, validation was performed in relation to specificity,
linearity, LOQ, LOD, accuracy, precision, robustness,
and solution stability. These parameters were validated
in agreement with the ICH guidelines.The linearity was performed by diluting the impurity
stock solution to the required concentrations. The solutions
were prepared at six concentration levels between 0.06 to
7.5 ppm for both SHH and MAP PGIs and were subjected
to linear regression analysis with the least squares method.
Calibration equation obtained from regression analysis was
used to calculate the corresponding predicted responses.
System precision of the mass spectrometric response was
established by injecting six individual preparations of the
standard solution. The method precision was evaluated by
spiking each analyte and determining the percent relative
standard deviation (%RSD). LOD and LOQ were evaluated
by considering the impurity concentration that would yield
S/N ratios of 3:1 and 10:1, respectively. The precision of
LOD and LOQ values were experimentally verified by six
injections of standard solutions of the compounds at the
determined concentrations. Recoveries of SHH and MAP
PGIs in spiked samples were studied at three different
concentration levels, viz. 0.06, 1.5, and 3.0 ppm. At each
concentration level, three independent sample prepara-
tions were injected, and the percentage recoveries were
determined by comparing the concentration of the spiked
sample obtained with the concentration of the spiking
standard. The robustness of the method was evaluated by
changing mobile phase flow and column temperature, and
the stability of the impurities in the sample solution was
evaluated by analyzing spiked sample solution at different
time intervals at room temperature.
Results and discussion
Optimization of sample preparation
Sample preparation is an important part in the pharma-
ceutical impurity analysis, because matrix effects in trace
analysis were enlarged, causing loss of sensitivity, abnor-
mal recovery, and analyte instability. Different diluents
were evaluated with respect to chromatographic efficiency.
Solubility of both celecoxib and impurities were good in
methanol. Good response and proper peak shapes were
obtained for both the impurities when methanol was used
as the diluent. Good recoveries (95.0% to 104.0%) were
also observed for both SHH and MAP PGIs when
methanol was used as a diluent. Therefore, methanol was
employed as the diluent throughout the analysis.
Column selection and separation
The present method was developed by testing different
stationary phases to achieve good separation of the im-
purity peaks from drug substance peak. It is important
to achieve proper separation among the two PGIs and
celecoxib, because of similar chemical structure of two
PGIs and celecoxib. In order to obtain a short analysis
time, various analytical columns like Kromasil C18
150 mm × 4.6 mm, 3.5 μm (Altmann Analytik, Munich,
Germany), Hypersil BDS C8 150 mm × 4.6 mm, 3.5 μm
Table 1 The precision at LOD and LOQ concentrations of
SHH and MAP PGIs









1 2,196 6,280 2,496 7,109
2 2,094 6,300 2,344 7,350
3 2,173 6,351 2,342 6,973
4 2,085 6,240 2,349 7,300
5 2,210 6,190 2,488 7,246
6 2,090 6,250 2,371 6,920
Mean 2,141.33 6,268.50 2,398.66 7,149.66
Standard deviation 57.88 55.22 73.58 177.52
%RSD 2.70 0.88 2.94 2.48
Concentration 0.02 ppm 0.06 ppm 0.02 ppm 0.06 ppm
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3.5 μm (Waters, Milford, MA, USA), and Zorbax Rx
C8 150 mm × 4.6 mm, 3.5 μm (Agilent Technologies,
Inc., Santa Clara, CA, USA) were evaluated. The tested
columns were checked under the same conditions;
with the Kromasil C18 and Zorbax Rx C8 columns, the
peaks of impurities were overlapped with celecoxib
peak. The resolution between celecoxib and impurities
were poor with Hypersil BDS C8 column. On Symmetry
C18 column (150 mm × 4.6 mm, 3.5 μm), the separation
and responses for both the impurities and celecoxib were
found good. On this column, the analytes were well
retained and separated from each other and from the drug
substance. This separation is achieved due to polar group
technology that ‘shields’ the silica residual silanol surface
from highly basic analytes; this reduced silanol activity
for the symmetry column significantly improved the
peak shape and resolution. Different compositions of
mobile phases using 10 mM ammonium acetate and
5.0 mM ammonium acetate with acetonitrile were tested;
finally, good separation and response were observed at
a ratio of 5.0 mM ammonium acetate-acetonitrile
(30:70, v/v). Both isocratic and gradient elution modes
were evaluated. Isocratic elution was observed to be
more efficient in achieving optimum separation of impur-
ities from each other with respect to drug substance peak.
The column was thermostated at 40°C to avoid any shift
in retention time. Retention times of SHH and MAP PGIs
were observed at 3.08 and 4.02 min, respectively. Peaks
were well separated from the drug substance peak
(5.79 min).Figure 2 Representative mass spectra of SHH, MAP PGIs, and celecoxOptimization of MS-MS parameters
Selection of a detection method is also the most important
part of pharmaceutical impurity analysis. From the instru-
ment simplicity and availability, first, we have evaluated
with HPLC-UV and GC-FID. However, on these techniques
sufficient sensitivity for the trace level analysis of SHH and
MAP PGIs was not achieved. In view of this, a sensitive
and specific mass LC-MS/MS technique in MRM mode
was evaluated for the quantification of SHH and MAP PGIs
in celecoxib drug substance. Then, the possibility of using
electrospray ionization (ESI) source under positive ion
detection mode was evaluated during the early stage ofib.
Figure 3 Linearity plot of SHH and MAP PGIs at 0.06- to 7.5-
ppm concentration levels.
Table 3 The recovery data of SHH and MAP PGIs at three
different concentrations
Parameter SHH MAP
Accuracy at LOQ level (n = 3)
Amount added (ppm) 0.06 0.06
Amount recovered (ppm) 0.057 0.059
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mode was much higher than that in negative mode.
Further, the method development was carried out with
ESI source operated in positive polarity mode. The ion
source parameters were optimized to get proper response.
The representative mass spectra of SHH, MAP, and
celecoxib are shown in Figure 2.
Method validation
In order to prove that the method is capable of its
intended use, the newly developed method for the
quantification of SHH and MAP PGIs in celecoxib
drug substance was validated according to the inter-
national guidelines (Vijaya Bhaskar Reddy et al. 2013;
ICH 2005).
Limit of detection and limit of quantification
The method validation was started by injecting 1.0-ppm
concentration of individual solutions of SHH and MAP
PGIs of each with respect to the drug substance concen-
tration of 10 mg/mL and determining their S/N ratios.
Now, to evaluate LOD and LOQ values, their concen-
trations were reduced sequentially such that they yield
S/N ratios as 3:1 and 10:1, respectively. Each predicted
concentration was verified for their precision by preparing
the solutions at predicted concentrations and injected
each solution six times for analyses. The LOD and LOQ
values calculated form S/N ratio was found to be 0.02
and 0.06 ppm, respectively. It is noteworthy that the
LOD values for both the impurities were below the re-
quired concentration limit (7.5 ppm) for PGIs in celecoxib
(Table 1).
Linearity
By MRM, the linearity of SHH and MAP PGIs was sat-
isfactorily demonstrated with a six-point calibration
graph between 0.06 and 7.5 ppm with respect to a sample
concentration of 10 mg/mL. The calibration curves were
produced by plotting the average of triplicate PGITable 2 Intra-day and inter-day precision of SHH and
MAP PGIs at 1.0-ppm concentration
Injection ID SHH (peak area) MAP (peak area)
Intra-day Inter-day Intra-day Inter-day
1 101,680 101,680 113,540 113,540
2 104,534 102,641 113,471 108,618
3 103,820 101,950 109,346 116,864
4 99,495 102,700 108,510 112,951
5 102,350 102,681 114,570 113,470
6 103,554 103,987 109,500 108,650
Standard deviation 1,826.69 801.93 252.78 3,194.58
%RSD 1.78 0.78 2.37 2.84injections against the concentration expressed in percent-
age. The slope, intercept, and correlation coefficient
values were derived from linear least squares regres-
sion analysis. The correlation coefficient obtained in
each case was >0.9998. The corresponding linearity data
is presented in Figure 3. The results indicated that an ex-
cellent correlation existed between the peak areas and the
concentrations of impurities.
Precision
The precision of the method was evaluated at two levels,
viz. repeatability and intermediate precision. Repeatability
was checked by calculating the %RSD of six replicate de-
terminations by injecting six freshly prepared solutions
containing 1.0 ppm each of the mixture of impurities on
the same day. The same experiments were done on six
different days to evaluate the intermediate precision.%recovery 95.3 98.6
%RSD 1.95 1.84
Accuracy at 100% level (n = 3)
Amount added (ppm) 1.5 1.5
Amount recovered (ppm) 1.479 1.521
%recovery 98.6 101.4
%RSD 1.95 1.84
Accuracy at 150% level (n = 3)
Amount added (ppm) 3.0 3.0
Amount recovered (ppm) 3.102 3.108
%recovery 103.4 103.6
%RSD 1.21 1.44
n, number of determinations.
Figure 4 Recovery chromatogram of SHH and MAP PGIs at LOQ concentration.
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3.0% for both the impurities; this confirmed an adequate
precision of the developed method.
Accuracy and specificity studies
When three pure and formulation sample solutions of
10 mg/mL of celecoxib were injected, impurities were
not at all detected in them. Hence, recovery studies by the
standard addition method were performed to evaluateFigure 5 Specificity chromatogram of celecoxib spiked with SHH andaccuracy and specificity. Accordingly, the accuracy of the
method was determined by spiking at (LOQ) 0.06-, 1.5-,
and 3.0-ppm concentrations separately to three batches of
pure and formulation solutions of celecoxib (10 mg/mL).
Each determination was carried out three times. The
recovery data is presented in Table 3, and the corre-
sponding chromatogram is shown in Figure 4. Satisfac-
tory recoveries of 95.3% to 98.6% for 0.06 ppm, 98.6%
to 101.4% for 1.5 ppm, and 103.4% to 103.6% forMAP PGIs.
Figure 6 Representative chromatograms of (a) blank and (b) formulation sample of celecoxib.
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these recoveries and %RSDs were satisfactory. The spe-
cificity of the method was established by injecting
blank celecoxib (tablet) solution and celecoxib spiked
with two PGIs. It was observed that the common ex-
cipients used in the tablets were not interfered at the
retention times of any PGIs and drug substance. The
corresponding specificity chromatogram is shown in
Figure 5. The developed method was also successfully
applied for the determination of SHH and MAP PGIs
in three different batches of celecoxib. In two batches,
the PGIs were not detected. In one of the batches of
celecoxib, only MAP was observed; however, its concen-
tration was below the specification. The corresponding
chromatogram is shown in Figure 6.Table 4 Robustness data of SHH and MAP PGIs at LOD
and LOQ concentrations
Parameter Actual Low High
Flow variation 0.7 0.63 0.77
Column oven temperature (°C) 40 38 42
SHH
%RSD at LOD 1.37 1.34 1.76
%RSD at LOQ 1.42 1.78 2.04
MAP
%RSD at LOD 0.68 1.42 0.74
%RSD at LOQ 2.14 1.63 1.91Robustness
The robustness of the method was studied with deliberate
modifications in the flow rate of the mobile phase and the
column temperature. The optimized flow rate of the mobile
phase was 0.7 mL/min, and the same was altered by 10% of
its flow, i.e., from 0.63 to 0.77 mL/min. The effect of col-
umn temperature on resolution was studied at 38°C and
42°C (altered by 2°C). However, the mobile phase compo-
nents were held constant as described above. As reported
in Table 4, the %RSD in both the cases does not exceeded
3.0%, which demonstrates the robustness of the method.
Solution stability
Stability of SHH and MAP PGIs in methanol was checked
by keeping them in an autosampler and observing the
variations in their peak areas. From the stability results,
we found that SHH and MAP were stable up to 48 h.




Theoretical concentration (ppm) 0.06 0.06
Percent recovery (n = 3)
At 0 h 98.2 ± 0.94 96.2 ± 1.24
At 12 h 101.4 ± 1.13 95.6 ± 0.91
At 24 h 102.6 ± 0.82 96.4 ± 0.88
At 48 h 99.8 ± 1.45 100.4 ± 1.36
n, number of determinations.
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The proposed method is a direct LC-MS/MS method for
the separation and quantification of SHH and MAP PGIs
in celecoxib drug substance. The method utilized MRM
mode for the quantitation, which provided the better
sensitivity. The method was fully validated and presents
good linearity, specificity, accuracy, precision, and robust-
ness, and it is also found to be simple, sensitive, selective,
cost effective, and stability indicating. The LOD and LOQ
of the method were found very low, as 0.02 and 0.06 ppm
for both SHH and MAP impurities. The proposed method
was successfully applied for the determination of the
two PGIs in three formulation batches of celecoxib.
The method presented here could be very useful to
monitor SHH and MAP PGIs in celecoxib during its
manufacturing.
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